SeaStar Medical

SeaStar Medical Holding Corporation is a healthcare and biotechnology company based in Denver, Colorado, founded in 2007. The company develops innovative therapies aimed at treating critically ill patients suffering from organ failure and severe hyperinflammatory conditions, particularly those caused by cytokine storms. The core technology of SeaStar Medical is the Selective Cytopheretic Device (SCD), a patented medical device that modulates the immune system by targeting overactive neutrophils and monocytes. The SCD therapy is designed to halt the cytokine storm, which can lead to multiorgan failure. SeaStar Medical's flagship product, QUELIMMUNE (SCD-PED), is the only FDA-approved therapy for life-threatening acute kidney injury due to sepsis in critically ill pediatric patients. The company is also conducting clinical trials for its SCD therapy in adult patients with acute kidney injury. In addition to acute kidney injury, SeaStar Medical is developing therapies for other critical conditions, including cardiorenal syndrome and hepatorenal syndrome. Their technology integrates with existing hemodialysis systems, aiming to improve patient recovery and resource utilization in critical care settings.

• Employees 19
• Founded 2018
• Annual Revenue $428000
• Total Funding $22900000